Palbociclib triggers cell cycle arrest by blocking retinoblastoma (Rb) phosphorylation through binding to the ATP binding site (8) and is approved for the treatment of hormonal receptor-positive, HER2- metastatic BC in combination with anti-hormonal therapy in Europe. This evidence concerns the gene RB1 and breast cancer.